Werewolf Therapeutics Inc
NASDAQ:HOWL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.71
7.91
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HOWL stock under the Base Case scenario is 1.54 USD. Compared to the current market price of 2.15 USD, Werewolf Therapeutics Inc is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Werewolf Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HOWL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Werewolf Therapeutics Inc
Balance Sheet Decomposition
Werewolf Therapeutics Inc
Current Assets | 125.8m |
Cash & Short-Term Investments | 122.8m |
Receivables | 464k |
Other Current Assets | 2.5m |
Non-Current Assets | 14.2m |
PP&E | 12.9m |
Other Non-Current Assets | 1.3m |
Current Liabilities | 12.5m |
Accounts Payable | 1.2m |
Accrued Liabilities | 11.2m |
Non-Current Liabilities | 38.2m |
Long-Term Debt | 25.6m |
Other Non-Current Liabilities | 12.6m |
Earnings Waterfall
Werewolf Therapeutics Inc
Revenue
|
3.4m
USD
|
Operating Expenses
|
-69.6m
USD
|
Operating Income
|
-66.2m
USD
|
Other Expenses
|
4.1m
USD
|
Net Income
|
-62.1m
USD
|
Free Cash Flow Analysis
Werewolf Therapeutics Inc
USD | |
Free Cash Flow | USD |
HOWL Profitability Score
Profitability Due Diligence
Werewolf Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Werewolf Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
HOWL Solvency Score
Solvency Due Diligence
Werewolf Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Werewolf Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HOWL Price Targets Summary
Werewolf Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HOWL is 12.24 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.
Dividends
Current shareholder yield for HOWL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
HOWL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.
Contact
IPO
Employees
Officers
The intrinsic value of one HOWL stock under the Base Case scenario is 1.54 USD.
Compared to the current market price of 2.15 USD, Werewolf Therapeutics Inc is Overvalued by 28%.